The TRAILBLAZER-ALZ 2 randomized Phase 3 trial found that donanemab slowed clinical progression in participants with early symptomatic Alzheimer disease and amyloid and tau pathology. The JAMA paper does not describe the treatment as a cure or as halting all cognitive decline. It reports differences between treatment and placebo groups over the study period. JAMA trial report
The double-blind, placebo-controlled study enrolled 1,736 participants at 277 medical research centers and hospitals in eight countries. Outcomes were assessed at 76 weeks. On the integrated Alzheimer Disease Rating Scale, both groups declined, but the decline was smaller in the donanemab group: in the combined study population, the reported mean change was −10.19 with donanemab and −13.11 with placebo.
Benefits must be read alongside harms. The report recorded amyloid-related imaging abnormalities involving edema or effusion in 24.0% of donanemab recipients, compared with 2.1% in the placebo group. Three deaths in the donanemab group and one in the placebo group were considered treatment related.
The results concern the trial’s selected population, treatment protocol and follow-up period. They do not establish the same outcome for every person with dementia. The registered study is NCT04437511. This summary is reporting, not individual treatment advice. Trial registration
Archive note: the earlier ALZ-7 drug, population and response claims were unsupported.